RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved drug-like properties, with an IC50 of 63.8 nM.
IC50&Target
ROR-γ
63.8 nM (IC50)
体外研究
RORγt inverse agonist 13 (Compound 3i) exhibits activity with an inhibition of 76% at 0.3 µM in Th17 cell differentiation assay.
体内研究
RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model.
Animal Model:
Imiquimod (IMQ)-induced psoriasis mice model.
Dosage:
25 mg/kg.
Administration:
Orally, twice daily.
Result:
Brought in a significant reduction in clinical severity of psoriasis as measured through the ear erythema, back skin erythema and scaliness scales.
Animal Model:
Male CD-1 Mice.
Dosage:
1 mg/kg (i.v.) and 5 mg/kg (p.o.)(Pharmacokinetic Analysis).
Administration:
IV or PO, single dose.
Result:
Cmax: 609.67 ng/mL (PO), 1550 ng/mL (IV).
T1/2: 3.63 h (PO), 3.04 h (IV).
分子式
C23H17Cl2F3N2O4
分子量
513.29
CAS号
2170477-75-3
运输条件
Room temperature in continental US; may vary elsewhere.